Author: claimsbot

1. A process for producing an erythromycin compound which is a 2-O-acetyl-4-O-formyl-8,9-anhydroerythromycin A 6,9-hemiketal compound 4 represented by the formula (4):
13
wherein R1 and R2 each independently represent a lower alkyl group,
which comprises reacting a 2-O-acetylerythromycin A compound 2 represented by the formula (2):
14
wherein R1 and R2 have the same meanings as defined above,
with a formylating agent to obtain a 2-O-acetyl-4-O-formylerythromycin A compound 3 represented by the formula (3):
15
wherein R1 and R2 have the same meanings as defined above,
then, reacting Compound 3 with an acid to subject to hemiketalation, and adding an aqueous basic solution in an aqueous solution to precipitate Compound 4 as free crystals.
2. The preparation process according to claim 1, wherein the process further comprises a step of reacting an acetylating agent to the erythromycin A compound 1 represented by the formula (1):
16
wherein R1 and R2 each independently represent a lower alkyl group,
to obtain Compound 2 before reacting the formylating agent with Compound 2 in the process according to claim 1.
3. The preparation process according to claim 2, wherein after reacting with the acetylating agent, the obtained Compound 2 is reacted with the formylating agent continuously without subjecting to isolation and purification thereof.
4. The preparation process according to any one of claims 1 to 3, wherein after reacting with the formylating agent, the obtained Compound 3 is subjected to hemiketalation continuously without subjecting to isolation and purification thereof.
5. The preparation process according to any one of claims 1 to 4, wherein after subjecting to hemiketalation, an aqueous basic solution is added to a reaction mixture to make a pH of the reaction mixture to 6.5 to 10.0.
6. The preparation process according to any one of claims 1 to 5, wherein R1 and R2 are each a methyl group.
7. The preparation process according to any one of claims 1 to 5, wherein R1 is a methyl group, and R2 is an isopropyl group.
8. The preparation process according to any one of claims 1 to 7, wherein the formylating agent is selected from the group consisting of a mixture of formic acid-acetic acid compound and 1-formylimidazole.
9. The preparation process according to any one of claims 1 to 7, wherein the formylating agent is selected from the group consisting of formic acid-acetic anhydride, sodium formate-acetyl chloride and 1-formylimidazole.
10. The preparation process according to any one of claims 1 to 7, wherein the formylating agent is selected from the group consisting of formic acid-acetic anhydride and sodium formate-acetyl chloride.
11. The preparation process according to any one of claims 2 to 10, wherein the acetylating agent is selected from the group consisting of an acetic anhydride, an acetyl halide, an acetate and 1-acetylimidazole.
12. The preparation process according to any one of claims 2 to 10, wherein the acetylating agent is selected from the group consisting of acetic anhydride, acetyl chloride, sodium acetate and 1-acetylimidazole.
13. The preparation process according to any one of claims 2 to 10, wherein the acetylating agent is selected from the group consisting of acetic anhydride and acetyl chloride.
14. A process for isolating and purifying a 2-Q-acetyl-4-O-formyl-8,9-anhydroerythromycin A 6,9-hemiketal 5 compound represented by the formula (4):
17
wherein R1 and R2each independently represent a lower alkyl group,
wherein the preparation process comprises adding a basic solution to an aqueous solution containing the compound and impurities to precipitate the compound from the aqueous solution as free crystals.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method of managing a resource of a communication device, the communication device configured to process and communicate medical data in addition to other data, the method comprising:
determining whether to switch to a medical mode based on at least one signal;
in response to determining to switch to the medical mode, switching to the medical mode;
weighing a resource status associated with a plurality of resources used by the communication device against a medical data criticality associated with the medical data managed by the communication device; and
allocating the plurality of resources on a sliding priority scale.
2. The method of claim 1, wherein the allocating further comprises allocating a resource of the plurality of resources preferentially to the medical data over the other data.
3. The method of claim 1, wherein the at least one signal is one of an on-signal and an off-signal.
4. The method of claim 1, wherein the at least one signal is one of an always on-signal and an always off-signal.
5. The method of claim 1, wherein the determining whether to switch is based on one of:
a manual control;
a first processor control that automatically switches into the medical mode or a regular mode based on input from the plurality of resources;
a second processor control that switches into the medical mode or the regular mode based on signaling from the plurality of resources; and
a factory setting.
6. The method of claim 1, wherein weighing a resource status is performed by a remote resource separate from the communication device.
7. The method of claim 1, wherein allocating the plurality of resources includes at least one of:
diverting at least a first part of the medical data to a first onboard resource of the communication device; or
diverting at least a second part of the medical data from a second onboard resource to a remote resource of the communication device.
8. The method of claim 1, wherein allocating the plurality of resources includes at least one of:
ensuring a predetermined portion of use of the resource is available for managing the medical data; or
ensuring the medical data has precedence over the other data with regard to the use of a third onboard resource of the communication device.
9. The method of claim 1, wherein allocating the plurality of resources includes dedicating the resource exclusively to managing the medical data and preventing the resource from being used for the other data.
10. The method of claim 1, wherein allocating the plurality of resources includes diverting the medical data to the resource, wherein the resource is a dedicated resource used exclusively for managing the medical data.
11. The method of claim 1, wherein allocating the plurality of resources includes preventing the plurality of resources from being used for managing the other data.
12. The method of claim 1, further comprising:
activating a dedicated resource in response to determining to switch to the medical mode, wherein the dedicated resource is used for the medical data and restricted from being used for the other data.
13. The method of claim 12, wherein the activated dedicated resource is used for the other data to a limited extent based on a combined weighting given to the resource status and the medical data.
14. The method of claim 12, wherein the activated dedicated resource is a system on chip (SOC) onboard the communication device.
15. The method of claim 14, where in the SOC is a medical grade SOC.
16. A communication device configured to process and communicate medical data in addition to other data, the communication device comprising:
a memory; and
a processor coupled to the memory, wherein the processor is configured with processor-executable instructions to perform operations comprising:
determining whether to switch to a medical mode based on at least one signal;
in response to determining to switch to the medical mode, switching to the medical mode;
weighing a resource status associated with a plurality of resources used by the communication device against a medical data criticality associated with the medical data managed by the communication device; and
allocating the plurality of resources on a sliding priority scale.
17. The communication device of claim 16, wherein the memory and the processor are coupled and integrated together on a system on chip (SOC).
18. The communication device of claim 17, further comprising at least one of:
a radio coupled and integrated on the SOC; or
a power source coupled and integrated on the SOC.
19. A non-transitory processor-readable storage medium having stored thereon processor-executable instructions configured to cause a processor of a communication device, coupled to a memory, to perform operations for processing and communicating medical data in addition to other data comprising:
determining whether to switch to a medical mode based on at least one signal;
in response to determining to switch to the medical mode, switching to the medical mode;
weighing a resource status associated with a plurality of resources used by the communication device against a medical data criticality associated with the medical data managed by the communication device; and
allocating the plurality of resources on a sliding priority scale.
20. A method of managing a resource of a communication device, the communication device configured to process and communicate medical data in addition to other data, the method comprising:
receiving, at an inference engine of the communication device, a plurality of data associated with a user’s condition;
determining a medical data criticality by combining the plurality of data; and
determining a resource requirement based at least in part on the medical data criticality.
21. The method of claim 20, wherein the plurality of data is associated with at least two different types of data.
22. The method of claim 20, wherein the plurality of data comprises at least one of environmental data, context data, physiological and biological data, health record data, long-term historical health data, directly input data, individual health risk data, personal genomic data, behavioral data, or public alerts.
23. The method of claim 20, wherein the determining the medical data criticality comprises generating a criticality indicator corresponding to the medical data criticality.
24. The method of claim 23, wherein the generating the criticality indicator comprises:
comparing long-term historical health data associated with a patient with at least one temporal characteristic obtained from a sensor attached to a user;
detecting a change in the at least one temporal characteristic; and
changing the criticality indicator from a default low value to a high value.
25. The method of claim 24, further comprising providing the criticality indicator to onboard resource of the communication device.
26. The method of claim 24, further comprising providing the criticality indicator to a remote resource.
27. The method claim 24, wherein the determining the resource requirement comprises generating an indication of at least one action to be taken.
28. The method of claim 20, further comprising:
determining a necessary resource for completing at least one action during a particular period of time; and
determining a resource allocation in a medical mode based on the determined necessary resource.
29. The method of claim 20 further comprising exchanging information associated with the medical data criticality with at least one of a clinical decision support system or a knowledge support system.
30. The method of claim 20, wherein at least one of determining the medical data criticality or determining the resource requirement is performed using a state machine.

1. A method of communicating with a wireless station, said method being performed in an access point, said method comprising:
communicating with said wireless station based on a point-to-point channel to determine at a first time instance, a future time instance at or after which a subsequent communication is expected to be received from said wireless station at said access point;
receiving at a second time instance said subsequent communication destined to said access point, wherein said second time instance is at or after said future time instance; and
powering down at least a portion of a circuit contained in said access point in at least a partial duration between said first time instance and said future time instance, to thereby reduce power consumption in said access point.
2. The method of claim 1, further comprising:
creating a data value in said access point; and
transmitting said data value to said wireless station in a duration in which said portion of said circuit is powered on.
3. The method of claim 2, wherein said portion of said circuit comprises a receive block of said access point.
4. The method of claim 3, wherein said wireless station is a mobile phone and said access point is a monitoringcontrolling device.
5. The method of claim 3, wherein said access point is a blood pressure measuring device and said data value represents a magnitude of blood pressure measured on a person wearing said access point.
6. The method of claim 5, wherein said blood pressure measuring device is designed to receive commands indicating a corresponding rate at which said blood pressure is to be measured and transmitted, wherein said subsequent communication is a command, and said future time instance represents a time instance at which said command is expected to be received at said AP.
7. The method of claim 3, wherein each of said access point and said wireless station is designed according to 802.11 standard.
8. A non-transitory computer readable medium storing one or more sequences of instructions for causing an access point to communicate with a wireless station, said one or more sequences of instructions comprising:
a first set of instructions constituting a communication module;
a second set of instructions constituting an application module, wherein execution of said application module causes said access point to perform the actions of:
communicating, based on a communication capability provided by said communication module, with a peer application executing on said wireless station to determine at a first time instance, a future time instance at or after which a subsequent communication is expected to be received from said wireless station at said access point;
receiving at a second time instance said subsequent communication destined to said access point, wherein said second time instance is at or after said future time instance; and
powering down at least a portion of a circuit contained in said access point in at least a partial duration between said first time instance and said future time instance, to thereby reduce power consumption in said access point.
9. The non-transitory computer readable medium of claim 8, wherein execution of said application module further causes said access point to perform the actions of:
creating a data value in said access point; and
transmitting said data value to said wireless station in a duration in which said portion of said circuit is powered on.
10. The non-transitory computer readable medium of claim 9, wherein said portion of said circuit comprises a receive block of said access point.
11. The non-transitory computer readable medium of claim 10, wherein said wireless station is a mobile phone.
12. The non-transitory computer readable medium of claim 10, wherein said access point is a blood pressure measuring device and said data value represents a magnitude of blood pressure measured on a person wearing said access point.
13. The non-transitory computer readable medium of claim 12, wherein said blood pressure measuring device is designed to receive commands indicating a corresponding rate at which said blood pressure is to be measured and transmitted, wherein said subsequent communication is a command, and said future time instance represents a time instance at which said command is expected to be received at said AP.
14. The non-transitory computer readable medium of claim 10, wherein each of said access point and said wireless station is designed according to 802.11 standard.
15. An access point (AP) comprising:
a memory to store instructions;
a processor to retrieve instructions from said memory and to execute said instructions, wherein execution of said retrieved instructions causes said access point to perform the actions of:
communicating with a wireless station based on a point-to-point channel to determine at a first time instance, a future time instance at or after which a subsequent communication is expected to be received from said wireless station at said access point;
receiving at a second time instance said subsequent communication destined to said access point, wherein said second time instance is at or after said future time instance; and
powering down at least a portion of a circuit contained in said access point in at least a partial duration between said first time instance and said future time instance, to thereby reduce power consumption in said access point.
16. The AP of claim 15, wherein execution of said retrieved instructions causes said AP to further perform the actions of:
creating a data value in said access point; and
transmitting said data value to said wireless station in a duration in which said portion of said circuit is powered on.
17. The AP of claim 16, wherein said portion of said circuit comprises a receive block of said access point.
18. The AP of claim 17, wherein said wireless station is a mobile phone and said access point is a monitoringcontrolling device.
19. The AP of claim 17, wherein said access point is a blood pressure measuring device and said data value represents a magnitude of blood pressure measured on a person wearing said access point.
20. The AP of claim 19, wherein said blood pressure measuring device is designed to receive commands indicating a corresponding rate at which said blood pressure is to be measured and transmitted, wherein said subsequent communication is a command, and said future time instance represents a time instance at which said command is expected to be received at said AP.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A topical pharmaceutical composition comprising mupirocin and beclomethasone.
2. The topical pharmaceutical composition according to claim 1, wherein said composition is an ointment, cream, lotion, solution or gel.
3. The topical pharmaceutical composition according to claim 1 or 2, further comprising poly (substituted or unsubstituted alkylene) glycol or a derivative thereof and a pharmaceutically acceptable carrier.
4. The topical pharmaceutical composition according to any of claims 1-3, comprising mupirocin in the range of about 1-5% ww and beclomethasone in the range of about 0.001-1% ww based on the total weight of the composition.
5. The topical pharmaceutical composition according to claim 4, wherein mupirocin content is about 2% ww and beclomethasone content is about 0.025% ww based on the total weight of the composition.
6. The topical composition according to any of the preceding claims, further comprising solvents, vehicles, ointmentcream bases, emulsifiers, preservatives, buffers, emollients, humectants, surfactants, and transport enhancers or mixtures there of.
7. A process for preparing a topical composition comprising:
i) melting and mixing together one or more solid or semi-solid vehicles;
ii) adding mupirocin and beclomethasone to the mixture of step (i) while stirring; and
iii) mixing until the temperature of the composition drops below 40\xb0 C.
8. The process according to claim 7, wherein the one or more solid or semi-solid vehicles comprises poly (substituted or unsubstituted alkylene) glycol or a derivative thereof.
9. Use of mupirocin and beclomethasone in the preparation of a medicament for the treatment of infected dermatoses caused by bacteria susceptible to mupirocin.
10. Use of mupirocin and beclomethasone in the preparation of a medicament for the treatment or prevention of secondary bacterial infections in patients of steroid responsive dermatoses.
11. Use of a pharmaceutical composition according to any of claims 1-6 for the treatment of infected dermatoses caused by bacteria susceptible to mupirocin.
12. Use of a pharmaceutical composition according to any of claims 1-6 for the treatment or prevention of secondary bacterial infections in patients of steroid responsive dermatoses.
13. A method for the treatment of infected dermatoses caused by bacteria susceptible to mupirocin comprising administering an effective amount of a composition comprising mupirocin and beclomethasone.
14. A method for the treatment or prevention of secondary bacterial infections in patients of steroid-responsive dermatoses comprising administering an effective amount of a composition comprising mupirocin and beclomethasone.
15. The method according to claim 13 or 14, wherein the dosage strength of mupirocin is in the range of 1-5% ww, and the dosage strength of beclomethasone is in the range of 0.005-1% ww based on the total weight of the composition.
16. The method according to claim 15, wherein the dosage strength of mupirocin is about 2% ww and the dosage strength of beclomethasone is about 0.025% ww based on the total weight of the composition.